Hospitalized Covid-19 patients could have more options for therapies that shorten their stays and keep them off ventilators if a clinical trial announced Friday shows they work.
The National Institutes of Health is studying whether drugs that regulate the immune system known as immune modulators can help Covid-19 patients who develop a type of inflammation that’s linked to life-threatening conditions, such as fluid in the lungs and multiple organ failure.
The clinical trial marks the latest effort under ACTIV, the NIH’s partnership with industry to home in on the most promising vaccine and therapy research for Covid-19. The study ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.